Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates

Drugs.com MedNews


 QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Babette Aicher, PhD, Director of Preclinical Development, will be making a poster presentation on updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models, at the upcoming American Association for Cancer Research ("AACR") annual meeting, which will be held April 6-10, 2013, in Washington D.C. The study is funded through a grant from the German Ministry of Education and Research.

 "....According to the literature, LHRH receptors occur in a number of human tumors, specifically in about 80% of ovarian and endometrial cancers. They are also expressed in prostate, urinary bladder and triple-negative breast cancer, while they are rarely found in normal tissues, except for the pituitary gland and reproductive organs. The LHRH receptor displays ideal properties for selective drug targeting.....